Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 40Lung Neoplasms 32Multiple Myeloma 24Leukemia, Myeloid, Acute 24Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Breast Neoplasms 19Urinary Bladder Neoplasms 17Pancreatic Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Melanoma 14Carcinoma, Renal Cell 12Sarcoma 11Glioma 11Carcinoma, Transitional Cell 11Mouth Neoplasms 10Fallopian Tube Neoplasms 10Endometrial Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neuroblastoma 9Laryngeal Neoplasms 9Glioblastoma 9Carcinoma 9Burkitt Lymphoma 9Stomach Neoplasms 8Oropharyngeal Neoplasms 8Osteosarcoma 7

Interventions

pembrolizumab 1X-Rays 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Congresses as Topic 1Cisplatin 1Carboplatin 1Brachytherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Locally Advanced Cervical Adenocarcinoma × Specimen Handling × Clear all
NCT07061977 2026-06-05

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
336 enrolled
Gynecologic

Locally Advanced Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡